Debt-to-equity of BridgeBio Pharma, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BridgeBio Pharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • BridgeBio Pharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -156%, a 2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

BridgeBio Pharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -156% +3% +2% 30 Sep 2025
Q2 2025 -157% +2% +1.4% 30 Jun 2025
Q1 2025 -159% -9% -5.9% 31 Mar 2025
Q4 2024 -166% -21% -15% 31 Dec 2024
Q3 2024 -159% -13% -8.6% 30 Sep 2024
Q2 2024 -159% -10% -7% 30 Jun 2024
Q1 2024 -150% +10% +6.2% 31 Mar 2024
Q4 2023 -144% +23% +14% 31 Dec 2023
Q3 2023 -147% +37% +20% 30 Sep 2023
Q2 2023 -149% +45% +23% 30 Jun 2023
Q1 2023 -160% +57% +26% 31 Mar 2023
Q4 2022 -167% +92% +36% 31 Dec 2022
Q3 2022 -183% +149% +45% 30 Sep 2022
Q2 2022 -194% +462% +70% 30 Jun 2022
Q1 2022 -218% -3717% -106% 31 Mar 2022
Q4 2021 -259% -522% -199% 31 Dec 2021
Q3 2021 -332% -483% -320% 30 Sep 2021
Q2 2021 -656% -747% -816% 30 Jun 2021
Q1 2021 3500% 31 Mar 2021
Q4 2020 263% 31 Dec 2020
Q3 2020 151% 30 Sep 2020
Q2 2020 92% 30 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.